Maxwell Skor
Stock Analyst at Morgan Stanley
(1.91)
# 2,647
Out of 5,050 analysts
7
Total ratings
50%
Success rate
4.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Initiates: Overweight | $190 | $104.39 | +82.01% | 1 | Oct 16, 2025 | |
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $189.70 | -24.09% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $197.74 | +26.43% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $4.09 | +193.40% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.09 | +817.43% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.59 | +123.97% | 2 | Nov 20, 2024 |
Cidara Therapeutics
Oct 16, 2025
Initiates: Overweight
Price Target: $190
Current: $104.39
Upside: +82.01%
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $189.70
Upside: -24.09%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $197.74
Upside: +26.43%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $4.09
Upside: +193.40%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.09
Upside: +817.43%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.59
Upside: +123.97%